- Home
- GLPG vs WWW Comparison
GLPG vs WWW Comparison
Compare GLPG & WWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | WWW |
|---|---|---|
| Founded | 1999 | 1883 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | WWW |
|---|---|---|
| Price | $32.44 | $18.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $31.33 | $25.43 |
| AVG Volume (30 Days) | 110.6K | ★ 1.5M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | $336,643,201.00 | ★ $1,851,500,000.00 |
| Revenue This Year | $3.61 | $7.35 |
| Revenue Next Year | N/A | $5.41 |
| P/E Ratio | ★ N/A | $17.39 |
| Revenue Growth | ★ 10.31 | 3.61 |
| 52 Week Low | $22.36 | $9.58 |
| 52 Week High | $37.78 | $32.80 |
Technical Indicators
Market Signals| Indicator | GLPG | WWW |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 50.76 |
| Support Level | $31.41 | $17.14 |
| Resistance Level | $31.98 | $18.72 |
| Average True Range (ATR) | 0.50 | 0.73 |
| MACD | 0.19 | 0.59 |
| Stochastic Oscillator | 86.33 | 84.61 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.